ABCB5 and recessive dystrophic epidermolysis bullosa: ,15,16,17 In the case of RDEB, treatments under investigation include protein replacement therapy using topical, intradermal, or intravenous administrations of recombinant human C7 and cell therapy involving bone marrow stem cells, gene-corrected RDEB fibroblasts, or allogeneic ABCB5+ mesenchymal stromal cells.52